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Objectives We sought to assess the effect of atrial fibrillation (AF) on atrial thrombogenesis in humans by determining the
impact of rate and rhythm.
Background Although AF is known to increase the risk of thromboembolic stroke from the left atrium (LA), the exact mecha-
nisms remain poorly understood.
Methods We studied 55 patients with AF who underwent catheter ablation while in sinus rhythm; 20 patients were in-
duced into AF, 20 patients were atrial paced at 150 beats/min, and 15 were control patients. Blood samples
were taken from the LA, right atrium, and femoral vein at baseline and at 15 min in all 3 groups. Platelet activa-
tion (P-selectin) was measured by flow cytometry. Thrombin generation (thrombin-antithrombin [TAT] complex),
endothelial dysfunction (asymmetric dimethylarginine [ADMA]), and platelet-derived inflammation (soluble CD40
ligand [sCD40L]) were measured using enzyme-linked immunosorbent assay.
Results Platelet activation increased significantly in both the AF (p  0.001) and pacing (p  0.05) groups, but de-
creased in control patients (p  0.001). Thrombin generation increased specifically in the LA compared with the
periphery in both the AF (p  0.01) and pacing (p  0.01) groups, but decreased in control patients (p 
0.001). With AF, ADMA (p  0.01) and sCD40L (p  0.001) levels increased significantly at all sites, but were
unchanged with pacing (ADMA, p  0.5; sCD40L, p  0.8) or in control patients (ADMA, p  0.6; sCD40L,
p  0.9).
Conclusions Rapid atrial rates and AF in humans both result in increased platelet activation and thrombin generation. Pro-
thrombotic activation occurs to a greater extent in the human LA compared with systemic circulation. AF addi-
tionally induces endothelial dysfunction and inflammation. These findings suggest that although rapid atrial
rates increase the thrombogenic risk, AF may further potentiate this risk. (J Am Coll Cardiol 2013;61:852–60)
© 2013 by the American College of Cardiology Foundation
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stroke in the absence of valvular heart disease (1). Although
epidemiological studies have linked various clinical and
echocardiographic risk factors to stroke, the exact mecha-
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function, it has been increasingly recognized that AF may in
itself exhibit a prothrombotic state (2). There have been
suggestions that atrial flutter, a more organized rhythm,
may also be associated with an increased risk of stroke (3).
However, the mechanisms by which rapid atrial rates and/or
rhythm contribute to left atrial (LA) thrombogenesis have
not been well studied.
Several studies have found baseline regional differences in
platelet activation and hypercoagulability in the LA com-
pared with systemic circulation in patients with valvular and
nonvalvular AF (4,5), suggesting local contributing factors.
Animal studies have demonstrated increased platelet acti-
vation and endothelial dysfunction with acute AF (6,7).
However, the acute effect of AF on thrombogenesis in the
human LA has never been studied before.
We hypothesized that acute-onset AF results in increased
prothrombotic risk (by platelet activation, thrombin gener-
ation, endothelial dysfunction, and inflammation) within
the human atria. Furthermore, we aimed to distinguish
whether this effect was rate or rhythm related.
Methods
Study population. The study comprised 55 patients with a
history of AF and 15 patients with left-sided accessory
pathways as a reference group who underwent catheter
ablation. Consecutive patients with paroxysmal or persistent
AF who were in sinus rhythm (SR) 48 h before the
procedure (by continuous monitoring) were included. Ex-
clusion criteria were history of valvular heart disease, left
ventricular dysfunction, previous myocardial infarction, un-
stable angina, surgical or ablation procedure within the
preceding 3 months, congenital heart disease, chronic in-
flammatory condition, chronic infection, chronic renal fail-
ure, chronic liver disease, and patients on antiplatelet agents.
All patients underwent baseline transthoracic echocardi-
ography and transesophageal echocardiography within 2
days of the procedure (8). All antiarrhythmic medications
were ceased 5 half-lives before the procedure. All patients
underwent anticoagulation with warfarin to maintain their
international normalized ratio between 2 and 3 for 6
weeks before the procedure. Warfarin was stopped 7 days
before the procedure and substituted with enoxaparin at a
dose of 1 mg/kg twice a day until 12 h before the
procedure.
All patients provided written informed consent to the
study protocol, which was approved by the Human Re-
search Ethics Committee of the Royal Adelaide Hospital,
Adelaide, Australia.
Electrophysiology study and ablation. Electrophysiologi-
cal study and ablation were performed with sedation using
midazolam and fentanyl. The technique used for mapping
and ablation of AF in our laboratory was previously de-
scribed (9). In brief, the following catheters were utilized for
the procedure: 1) 10 pole catheter (Daig Electrophysiology,Minnetonka, Minnesota) posi-
tioned within the coronary sinus;
2) 10-pole circumferential cathe-
ter (Lasso; Biosense-Webster,
Diamond Bar, California) to
map the pulmonary veins; and 3)
a 3.5-mm-tip externally irrigated
ablation catheter (Thermocool,
Biosense-Webster) for ablation.
All patients underwent circum-
ferential ablation of the pulmo-
nary veins with the endpoint of
electrical isolation. Additional
substrate modification using ei-
ther linear ablation (roofline
and/or mitral isthmus) and/or
ablation of complex fraction-
ated atrial electrograms was undertaken in patients with
long episodes of AF (48 h), evidence of structural heart
disease, or with a large LA (largest dimension  57 mm).
Study protocol. For the clinical procedure, a conventional
single transeptal puncture was performed using an SLO
sheath (St. Jude Medical, St. Paul, Minnesota) and a
BRK-1 needle (Daig Corporation). The ablation catheter
was advanced through the same puncture into the LA.
Following transeptal puncture, and 5 min after intravenous
administration of unfractionated heparin (bolus of 100
IU/kg), blood samples were simultaneously collected from
the peripheral femoral venous (FV) sheath (systemic sam-
ple), right atrial (RA) sheath, and LA sheath. Samples from
the RA and LA were collected with care using a slow
withdrawal technique, with the sheath positioned in the
midchamber. Patients were then randomized either into the
AF group, pacing group, or to serve as control patients.
Of the 55 patients with a history of AF who presented in
SR, AF was induced by burst atrial pacing in 20 patients,
commencing at a cycle length of 250 ms and ramping down
to loss of 1:1 capture. This process was repeated up to 3
times from 3 sites, as required. Another 20 patients under-
went atrial pacing at 150 beats/min. The rate of atrial pacing
was limited to prevent induction of AF. To control for the
effects of the transeptal puncture and procedure duration, 15
patients served as a control group, who neither underwent
AF induction nor pacing. After 15 min of AF, atrial pacing,
or in control patients, blood sampling was repeated from the
LA, RA, and FV. No ablation was performed before the
completion of the study protocol.
In addition to the control group of AF patients, to
evaluate the effect of transeptal puncture on prothrombotic
markers, 15 non-AF patients with left-sided accessory
pathways who underwent an electrophysiological study and
transeptal puncture during this period were also recruited as
a reference group. Blood samples were obtained from the
LA, RA, and FV following transeptal puncture at baseline.
Abbreviations
and Acronyms
ADMA  asymmetric
dimethylarginine
AF  atrial fibrillation
CV  coefficient of
variation
FV  femoral vein
LA  left atrium
RA  right atrium
sCD40L  soluble CD40
ligand
SR  sinus rhythm
TAT 
thrombin-antithrombin-complexWith the same exclusion criteria, consecutive patients with
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evaluated.
Blood analysis. WHOLE BLOOD FLOW CYTOMETRY. Blood
as collected utilizing a slow withdrawal technique, with
he first 10 mL discarded, and immediately transferred into
itrated tubes. Flow cytometry was performed within 24 h.
he surface expression of the platelet activation receptor,
D62P (P-selectin) was determined by flow cytometry
sing the CD62P monoclonal antibody. All monoclonal
ntibodies were obtained from BD Biosciences (San Jose,
alifornia). Citrated whole blood was diluted 1:9 in tris-
uffered saline (10-mM tris, 0.15-M sodium chloride)
efore 5-l antibody per 500-l tris-buffered blood was
dded (5). After incubation, the sample was fixed by adding
00 l of CellFix solution (BD Biosciences). The presence
f platelet expressing ligands was determined using flow
ytometry (FACSCanto, Becton Dickinson, Oxford,
nited Kingdom). Forward (size-dependent) scatter and
0° sideways (density-dependent) scatter were set at loga-
ithmic gain, and platelets were identified on the basis of
ize using a platelet immunoglobulin bead suspension. For
ach sample, platelets were further identified using the
latelet-specific CD42b antibody. The control ligand
mouse IgG2a-monoclonal antibody fluorescein isothiocya-
ate isotype control) was used to detect a nonspecific
ssociation and to define the threshold for activation-
ependent binding.
Data acquisition and analysis was performed with BD
ACSDiva Software Version 4.1.2 (Becton Dickinson).
he threshold for nonspecific binding (the percentage
efined with the immunoglobulin-G–fluorescein isothio-
yanate conjugate) was set at 1%. The percentage of
latelets expressing CD62P (P-selectin) monoclonal anti-
ody was defined as the fraction exhibiting specific binding.
he intra-assay coefficient of variation (CV), interassay CV,
nd lower limit of detection for platelet P-selectin were
.8%, 6.1%, and 1.1% positive, respectively.
ENZYME-LINKED IMMUNOSORBENT ASSAY. The obtained
lood samples were centrifuged at 2,500 g for 15 min at 4oC
nd stored at 80oC for batch analysis utilizing enzyme-
linked immunosorbent assay. Thrombin generation was
assessed by measuring thrombin-antithrombin (TAT) com-
plex (Siemens Healthcare Diagnostics, Marburg, Ger-
many). Endothelial dysfunction was assessed by measuring
asymmetric dimethylarginine (ADMA) (Immunodiagnos-
tik, Bensheim, Germany). Platelet-derived inflammation
was assessed by measuring soluble CD40 ligand (sCD40L)
(R&D Systems, Minneapolis, Minnesota), as per company
instructions. The intra-assay CV, interassay CV, and lower
limit of detection for each marker were: TAT, intra-assay
CV 4% to 6%, interassay CV 6% to 9%, lower limit of
detection 2.0 g/L; ADMA, intra-assay CV 5.7 %, inter-
assay CV 5.3 %, lower limit of detection 0.05 mol/L; and
CD40L, intra-assay CV 4.5% to 5.4 %, interassay CV 6.0%o 6.4%, lower limit of detection 4.2 pg/ml. All assays were
erformed in duplicate or triplicate.
tatistical analysis. All data are expressed as mean  SD
r number (percentages) for continuous and categorical
ariables, respectively, unless otherwise stated. Continuous
ariables were compared using 1-way analysis of variance.
ategorical variables were compared using Fisher’s exact or
earson’s chi-square tests as appropriate. Data were tested
or normality and log-transformed as appropriate. A con-
tant of 1 was added to ADMA values before log-
ransformation. To compare changes in the outcome mea-
ures over time between the sites within each group, a linear
ixed effects model was fitted to the data. In the model,
ime, sampling site, and the interaction between time and
ite were fitted as fixed effects, whereas individual patients
ere fitted as a random effect. This model takes the repeated
easurements over time into account. Where the interac-
ion was not significant, this was removed from the model
o that the main effects of time and site could be interpreted.
o compare between treatment groups, data were pooled
cross sites. A linear mixed effects model was fitted to the
ata. In the model, treatment group and time and the
nteraction between treatment group and time were fitted as
xed effects. Differences between sampling sites in the
eference group were analyzed using repeated measures
-way analysis of variance. Statistical significance was es-
ablished at p  0.05. All data were analyzed using PASW
tatistics 18 (version 18.0.0, SPSS, Chicago, Illinois).
esults
atient characteristics. There were no significant differ-
nces among the AF, pacing, and control groups with
egard to age, gender, comorbidities, medications, and
chocardiographic parameters (Table 1). There was no
ifference in mean ventricular rate between the AF and
acing groups.
latelet activation. Platelet P-selectin increased signifi-
antly with both AF induction (p  0.001) and pacing
(p  0.02), taking into consideration all sites, as shown in
Figures 1A and 1B. However, platelet P-selectin lev-
els decreased in control patients over time (p  0.001)
(Fig. 1C). There was a significant difference between the
sites measured (p  0.04) in the pacing group.
Thrombin generation. Thrombin generation (TAT) in-
creased significantly in the LA and RA compared with
peripheral samples in both the AF group (p  0.001, site
and time interaction) and the pacing group (p  0.002), as
shown in Figures 2A and 2B. Similar to the peripheral levels
in the AF and pacing groups, TAT levels in the control
group decreased with time (p  0.001), with no differences
in sites (p  0.6) (Fig. 2C).
Endothelial dysfunction. ADMA levels increased signifi-
cantly over time with the onset of AF (p 0.008) (Fig. 3A).
There was no change in ADMA levels with atrial pacing
(p  0.5) (Fig, 3B) or in control patients (p  0.6) (Fig.
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February 26, 2013:852–60 LA Thrombogenesis in AF3C). There was no significant difference in ADMA levels
between sites in the AF group (p  0.2).
Platelet-derived inflammation. Soluble CD40L levels in-
creased significantly over time with acute AF (p  0.001),
but were unchanged with atrial pacing (p  0.8) and in
control patients (p  0.9), as shown in Figures 4A to 4C.
here was no significant difference between the sites mea-
ured in the AF group (p  0.7).
F versus pacing. We compared intracardiac levels (LA
nd RA) of thrombin generation and platelet activation
Baseline Characteristics of Patients in the AF, Pacing, and ControTable 1 Baseline Characteristics of Patients in the AF, Pacing
AF Group
(n  20)
Age (yrs) 53.5 8.6
Male gender 10 (50.0)
BMI 31.5 8.0
Comorbidities
Congestive heart failure 0 (0)
NYHA functional class
I 13 (65.0)
II 7 (35.0)
III and IV 0 (0)
Hypertension 8 (40.0)
Diabetes mellitus 2 (10.0)
Stroke/transient ischemic attack 0 (0)
Mean CHA2DS2-VASc score 1.3 1.1
CHA2DS2-VASc score
0 5 (25.0)
1 8 (40.0)
2 7 (35.0)
Mean HAS-BLED score 0.6 0.6
HAS-BLED score
0–2 20 (100.0)
3 0 (0)
Usual medications
Flecainide 8 (40.0)
Sotalol 3 (15.0)
Beta-blockers 5 (25.0)
Calcium-channel blockers 4 (20.0)
Warfarin 15 (75.0)
Baseline heart rate (beats/min) 64.1 10.0
Atrial rate after 15 min (beats/min) 293.1 58.0
Ventricular rate after 15 min (beats/min) 108.4 23.0
Heparin bolus dose (IU) 8,438 1,632
ACT after 15 min (s) 237.4 27.4
Echocardiographic parameters
LA diameter 39.2 5.0
LA size 22.6 3.5
RA size 20.3 3.0
LVEF 61.6 6.7
LASEC grade 0 0
LAAEV (cm/s) 77.9 28.8
Values are mean  SD or n (%). *AF versus pacing group, p  0.01; AF versus control group, p 
 0.01; pacing versus control group, p  0.01.
ACT  activated clotting time; AF  atrial fibrillation; BMI  body mass index; CHA2DS2-VASc
isease, age 65 to 74 years, sex category (female); HAS-BLED hypertension, abnormal renal/live
lderly (e.g., age 65 years), drugs/alcohol concomitantly (1 point each); LA  left atrium; LAAEV
VEF left ventricular ejection fraction; NYHA  New York Heart Association,mong the AF, pacing, and control groups over time, given she difference between intracardiac and peripheral levels.
or ADMA and sCD40L levels, comparison was made
mong the groups, taking into account all sites, given that
o significant difference in sites were found.
Intracardiac platelet activation was significantly elevated
n the AF and pacing groups compared with the control
roup (Fig. 5A). However, the difference between AF and
acing was not significant (p  0.9). Intracardiac thrombin
eneration was significantly elevated in the AF and pacing
roups compared with the control group (p  0.01), but no
psControl Groups
Pacing Group
(n  20)
Control Group
(n  15) p Value
54.9 14.5 56.0 11.2 0.5
15 (75.0) 7 (46.7) 0.1
28.1 4.2 28.4 5.2 0.3
0 (0) 0 (0) NS
1.0
12 (60.0) 9 (60.0)
8 (40.0) 6 (40.0)
0 (0) 0 (0)
7 (35.0) 7 (46.7) 0.5
1 (5.0) 0 (0) 0.6
1 (5.0) 1 (6.7) 0.7
1.2 0.9 1.3 1.1 0.9
1.0
5 (25.0) 3 (20.0)
8 (40.0) 7 (46.7)
7 (35.0) 5 (33.3)
0.9 0.7 0.8 0.8 0.4
0.3
20 (100.0) 14 (93.3)
0 (0) 1 (6.7)
7 (35.0) 8 (53.3) 0.7
6 (30.0) 2 (13.3) 0.6
4 (20.0) 7 (46.7) 0.1
3 (15.0) 3 (20.0) 0.7
15 (75.0) 11 (73.3) 0.7
66.3 13.6 68.2 10.8 0.7
150.0 0 66.0 10.1 0.01*
114.6 31.2 66.0 10.1 0.01†
9,077 1,256 8,667 1,155 0.5
237.0 26.5 238.7 30.0 1.0
41.6 7.3 43.1 7.0 0.3
25.0 5.2 24.4 5.5 0.3
20.9 4.5 20.6 4.9 0.9
63.1 9.3 62.5 6.9 0.9
0.1 0.3 0.1 0.4 0.4
73.9 32.2 68.6 20.9 0.8
acing versus control group, p  0.01. †AF versus pacing group, p  1.0; AF versus control group,
estive heart failure, hypertension, age 75 years (doubled), diabetes, stroke (doubled), vascular
n (1 point each), stroke, bleeding tendency or predisposition, labile international normalized ratio,
atrial appendage emptying velocity; LASEC  left atrial spontaneous echocardiographic contrast;l Grou, and
0.01; p
 cong
r functioignificant difference was found between the AF and pacing
d
w
(
s
p
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ysfunction was significant in the AF group compared
ith the pacing group (p  0.05) and the control group
p  0.05) (Fig. 5C). In addition, inflammatory mediator
CD40L was raised in the AF group compared with the
acing group (p  0.01) and the control group (p  0.01)
(Fig. 5D).
Effect of transeptal puncture on prothrombotic markers.
To eliminate transeptal puncture as a possible cause of the
increased atrial prothrombotic markers observed in AF
patients, a cohort of patients who underwent ablation of a
left-sided accessory pathway was studied (8 men, 7 women;
mean age 38  7 years). Blood samples were obtained from
the LA, RA, and FV following transeptal puncture. There
were no significant differences in the levels of platelet
P-selectin (in mean  SEM) (log P-selectin 1.22  0.07 in
FV vs. 1.09  0.08 in RA vs. 1.18  0.07 in LA, p  0.2),
TAT (log TAT 1.29  0.08 in FV vs. 1.23  0.06 in RA
vs. 1.22  0.06 in LA, p  0.2), ADMA (log ADMA
0.13  0.01 in FV vs. 0.13  0.01 in RA vs. 0.13  0.01
in LA, p  0.5), and sCD40L (log sCD40L 2.20  0.05 in
FV vs. 2.20  0.05 in RA vs. 2.19  0.05 in LA, p  1.0)
Figure 1 Platelet Activation (Platelet P-selectin)
(A) Post-AF induction: *p  0.001 (time effect); p  0.1 (site effect). (B) Post-pa
0.05 (LA vs. P). (C) Control group: *p  0.001 (time effect); p  0.4 (site effect)
eral (femoral vein); RA  right atrium.
Figure 2 Thrombin Generation (TAT)
(A) Post-AF induction: *p  0.001 (site and time interaction); post-hoc tests at 15
time interaction); post-hoc tests at 15 min, p  0.01 (LA vs. P), p  0.01 (RA vs.
antithrombin complex; other abbreviations as in Figure 1.before or after transeptal puncture or between sampling sites
in these patients.
Discussion
This study provides new information on the relative contri-
bution of atrial rate and rhythm to thrombogenesis due to
atrial arrhythmias. By performing sampling from the LA,
RA, and the peripheral circulation, it demonstrates the
following: 1) rapid atrial rates are associated with increased
platelet activation and thrombin generation; 2) AF, al-
though also demonstrating changes in platelet activation
and thrombin generation, additionally leads to endothe-
lial dysfunction and activation of the inflammatory cas-
cade; and 3) interestingly, these factors occurred to a
much greater extent in the human LA compared with
peripheral circulation.
Left atrial platelet activation with AF and pacing. Pa-
tients with AF are recognized to exhibit a prothrombotic
state and abnormal platelet activation. This has been doc-
umented peripherally in various subsets of patients with AF
(10–12). Platelets play an essential role in thrombogenesis
by interacting with the endothelium, inflammatory cells,
p  0.02 (time effect); p  0.04 (site effect); post-hoc tests at 15 min, p 
expressed as mean  SEM. AF  atrial fibrillation; LA  left atrium; P  periph-
p  0.01 (LA vs. P), p  0.01 (RA vs. P). (B) Post-pacing: *p  0.002 (site and
) Control group: *p  0.001 (time effect); p  0.6 (site effect). TAT  thrombin-cing: *
. Datamin,
P). (C
857JACC Vol. 61, No. 8, 2013 Lim et al.
February 26, 2013:852–60 LA Thrombogenesis in AFand proteins from the coagulation cascade (5,13). Platelet
expression of P-selectin is commonly used as a marker of
platelet activation (5). Platelet P-selectin expression has
been associated with spontaneous echo contrast, presence of
LA thrombus or embolic events, and silent cerebral infarc-
tion in patients with AF (6,14).
Although several studies have shown increased platelet
activation in patients with AF compared with control
patients (11,15,16), other studies have shown that the
difference could be attributed to patient comorbidities (17).
These inconsistent results could partly be explained by
sampling from a heterogeneous population of AF patients,
sampling from peripheral versus central sites, and by mea-
suring at different times during AF rather than at a
predefined time (5,15). In this study, the effect of AF was
compared with each patient’s individual baseline state, and
sampling was performed in the LA at a predefined time. We
showed that AF per se and rapid atrial rates resulted in
elevated platelet activation.
In addition, platelet expression of P-selectin has been
suggested to be linked more with acute changes in platelet
activation (18). Although studies measuring patients with
AF at a baseline state have yielded varying results, studies
examining patients with acute episodes of AF have consis-
Figure 3 ADMA Levels
(A) Post-AF induction: *p  0.008 (time effect); p  0.2 (site effect). (B) Post-pa
(C) Control group: p  0.6 (time effect); p  0.9 (site effect). ADMA  asymmetr
Figure 4 Soluble CD40L Levels
(A) Post-AF induction: *p  0.001 (time effect); p  0.7 (site effect). (B) Post-pa
(C) Control group: p  0.9 (time effect); p  1.0 (site effect). Abbreviations as intently shown the involvement of platelets (15,16,19). Our
present findings are consistent with other studies in that
platelet activation is enhanced in the setting of acute AF,
after 3 to 12 h from peripheral sampling (16,19), and after
15 min from coronary sinus sampling (15). Platelet activa-
tion may thus play a role in the initiation of various
prothrombotic pathways in the acute or paroxysmal setting.
Left atrial thrombin generation with AF and pacing. In-
creased thrombin generation reflected by elevated TAT
levels has been found in the LA in patients with mitral
stenosis and AF (4). In chronic nonvalvular AF, increased
peripheral levels of coagulation markers have been demon-
strated (10,12). Abnormal expression of coagulation factors
in the atrial endocardium has been demonstrated in an
animal model of rapidly paced atria and in human patients
presenting with AF and cardiogenic thromboembolism
(20,21). Akar et al. (15) found increased thrombin genera-
tion and platelet activation with AF induction from samples
taken from the coronary sinus. In this study, acutely elevated
thrombin generation was observed specifically at the LA
and RA with the onset of AF and rapid atrial rates, which
was not seen in the peripheral circulation. This study
demonstrates that with the onset of AF and rapid atrial
rates, the LA is significantly more thrombogenic compared
 0.5 (time effect); p  0.3 (site effect).
thylarginine; other abbreviations as in Figure 1.
 0.8 (time effect); p  0.9 (site effect).
1.cing: p
ic dimecing: p
Figure
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pensity for LA thrombus formation and cardioembolic
stroke seen in these patients.
Endothelial dysfunction with AF induction. LA throm-
bus formation in AF has traditionally been attributed to
atrial mechanical dysfunction (8,22,23). However, it is now
accepted that multiple mechanisms contribute to LA
thrombus formation. Abnormal endothelial function (endo-
thelial dysfunction) has been shown in patients with AF and
is a component of Virchow’s triad for thrombogenesis
(2,24,25). ADMA is an endogenous inhibitor of endothelial
nitric oxide synthase and is known to result in endothelial
dysfunction in experimental human studies (26). Nitric
oxide has potent antithrombotic properties on the endothe-
lium and inhibits platelet and monocyte adhesion (27).
There is also evidence that ADMA mediates endothelial
dysfunction through oxidative stress (26). Clinically,
ADMA is associated with numerous cardiovascular condi-
tions and is a predictor of mortality in cardiovascular
patients (28,29).
The present study found that induction of AF was
associated with increased ADMA levels both peripherally
and in the human atria. The finding that induction of AF
upregulates ADMA is consistent with animal models, such
Figure 5 Change in Prothrombotic Markers Between Groups
(A) Change in intracardiac platelet activation between groups: p  0.001 (group a
ing vs. control group), p  0.9 (AF vs. pacing). (B) Change in intracardiac thrombi
*p  0.01 (AF vs. control group), †p  0.01 (pacing vs. control group), p  0.4 (
interaction); post-hoc tests: *p  0.05 (AF vs. control group), †p  0.05 (AF vs. p
els between groups: p  0.001 (group and time interaction); post-hoc tests: *p 
group). NB: Descriptive plots shown. Statistical analyses performed using mixed e
Figures 1 and 3.as the porcine AF model by Goette et al. (28). In anotheranimal study, Cai et al. (7) demonstrated decreased atrial
nitric oxide levels and endothelial nitric oxide synthase
expression in a rapid atrial pacing model of AF, which was
not seen in the control group of atrial pacing at 100
beats/min. Minamino et al. (6) found decreased nitric oxide
levels with associated increased P-selectin expression on
platelets in a canine model of AF. These findings suggest
that endothelial dysfunction induced by AF, mediated by
ADMA and the nitric oxide pathway, with resultant loss of
its antithrombotic properties, plays an important contribu-
tory role to thrombogenesis in patients with AF.
Inflammation with AF induction. Inflammation is being
increasingly recognized to play a significant role in the
genesis and perpetuation of AF (24,30). C-reactive protein
elevation is found in a stepwise fashion in patients with
increasing AF burden (31). Studies also show that high-
sensitivity C-reactive protein decreases after successful ab-
lation for long-standing persistent AF, suggesting that AF
itself may cause an inflammatory response (32).
Soluble CD40 ligand is increased in a number of cardio-
vascular settings (33). It is an important mediator in the
pathogenesis of atherothrombotic disease and predicts mor-
tality in patients with acute coronary syndromes (33,34).
CD40 ligand on activated platelets plays a pivotal role in
e interaction); post-hoc tests: *p  0.01 (AF vs. control group), †p  0.01 (pac-
ration between groups: p  0.001 (group and time interaction); post-hoc tests:
pacing). (C) Change in ADMA levels between groups. p  0.02 (group and time
, p  1.0 (pacing vs. control group). (D) Change in soluble CD40L (sCD40L) lev-
(AF vs. control group), †p  0.01 (AF vs. pacing), p  0.6 (pacing vs. control
models in which statistical significance was achieved. Abbreviations as innd tim
n gene
AF vs.
acing)
0.01
ffectsinflammatory responses by inducing endothelial secretion of
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promoting leukocyte recruitment (35). The CD40/CD40
ligand system has been proposed to provide an important
link between inflammation and thrombosis (34). This study
showed that the onset of AF increased sCD40L levels,
which was not seen with rapid atrial rates alone. This study
newly demonstrates that induction of AF in humans evi-
dently results in an increase in inflammatory signals. This
provides further insight into the link between inflammation
and thrombogenesis in patients with AF.
Clinical implications. This study demonstrates that AF or
abnormal rhythm per se confers additional prothombotic
effects in the LA beyond the patient’s comorbidities. These
findings point toward the benefit of maintaining SR and
provide an explanation for the “on-treatment” analysis of the
AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) study, which found the presence of
SR associated with a lower risk of death (36). The present
study also explains why increased AF burden and subclinical
atrial tachyarrhythmias (from implantable devices) are asso-
ciated with increased thromboembolic risk (37,38).
The finding that rapid atrial rates increase platelet and
thrombotic markers in the LA provides mechanistic insight
into thrombogenesis in atrial flutters, which may differ
slightly from AF, but nevertheless confer increased risk of
stroke (3,39,40). Furthermore, AF potentiates the throm-
bogenic risk over that of rate alone by activating other
mechanisms, such as endothelial dysfunction and the in-
flammatory cascade. This highlights the importance of
other therapeutic modalities that improve endothelial func-
tion and mediate the inflammatory response, and the
management of concomitant cardiovascular risk factors
associated with AF (30).
Study limitations. With access to the human LA, the
study would have been ethically impossible without the
administration of heparin. Heparin is known to possibly
affect TAT levels by initially enhancing binding before
causing irreversible inhibition of thrombin’s activity (41). In
our study, TAT levels at all sites in the control group and at
peripheral sites in the AF and pacing groups decreased with
time after the administration of heparin, which was consis-
tent with previous studies (15). However, despite decreased
TAT levels in control patients and in peripheral samples
with heparin, atrial levels significantly increased with AF
and atrial pacing.
The half-life of TAT is 15 min (42) and that of ADMA
is approximately 23 min (43), close to the study sampling
time. However, previous studies in humans have docu-
mented acute changes in levels of platelet P-selectin at 15
min (15), TAT at 15 min (15), and ADMA when measured
at 15-min intervals (44).
Underlying patient comorbidities could have contributed
to the prothrombotic state. However, the study measured
the effects of AF and pacing compared with each patient’s
baseline state. Hence, these results indicated that the effectsof AF and high atrial rates were in addition to a patient’s
underlying comorbidities.
Ventricular rate in both AF and pacing groups were faster
than the control group and could have contributed to the
increased effects. However, other studies have demonstrated
that patients controlled for ventricular rate either in a paced
setting or in paroxysmal supraventricular tachycardia did not
show any significant difference in prothrombotic markers
(11,15,19,28). The degree of rapid atrial pacing was limited
to 150 beats/min to prevent inadvertent induction of AF. It
is possible that the further findings observed in the AF
group were due to its higher atrial rates, although this could
not be explicated in the study.
Conclusions
Rapid atrial rates and AF in humans both result in increased
platelet activation and thrombin generation. Prothrombotic
activation occurs to a greater extent in the human LA
compared with systemic circulation. In addition, AF also
induces endothelial dysfunction and inflammation. These
findings suggest that although rapid atrial rates increase
thrombogenic risk, AF may further potentiate this risk.
Reprints and correspondence: Dr. Prashanthan Sanders, Centre
for Heart Rhythm Disorders (CHRD), Department of Cardiol-
ogy, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
E-mail: prash.sanders@adelaide.edu.au.
REFERENCES
1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an indepen-
dent risk factor for stroke: the Framingham Study. Stroke 1991;22:
983–8.
2. Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in
atrial fibrillation: Virchow’s triad revisited. Lancet 2009;373:155–66.
3. Sanders P, Morton JB, Morgan JG, et al. Reversal of atrial mechanical
stunning after cardioversion of atrial arrhythmias: implications for the
mechanisms of tachycardia-mediated atrial cardiomyopathy. Circula-
tion 2002;106:1806–13.
4. Yamamoto K, Ikeda U, Seino Y, et al. Coagulation activity is increased
in the left atrium of patients with mitral stenosis. J Am Coll Cardiol
1995;25:107–12.
5. Willoughby SR, Roberts-Thomson RL, Lim HS, et al. Atrial platelet
reactivity in patients with atrial fibrillation. Heart Rhythm 2010;7:
1178–83.
6. Minamino T, Kitakaze M, Sanada S, et al. Increased expression of
P-selectin on platelets is a risk factor for silent cerebral infarction in
patients with atrial fibrillation: role of nitric oxide. Circulation 1998;
98:1721–7.
7. Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric
oxide synthase expression and nitric oxide production in atrial fibril-
lation: potential mechanisms for atrial thrombosis and stroke. Circu-
lation 2002;106:2854–8.
8. Sanders P, Morton JB, Kistler PM, Vohra JK, Kalman JM, Sparks PB.
Reversal of atrial mechanical dysfunction after cardioversion of atrial
fibrillation: implications for the mechanisms of tachycardia-mediated
atrial cardiomyopathy. Circulation 2003;108:1976–84.
9. Stiles MK, John B, Wong CX, et al. Paroxysmal lone atrial fibrillation
is associated with an abnormal atrial substrate: characterizing the
“second factor.” J Am Coll Cardiol 2009;53:1182–91.
10. Mondillo S, Sabatini L, Agricola E, et al. Correlation between left
atrial size, prothrombotic state and markers of endothelial dysfunction
in patients with lone chronic nonrheumatic atrial fibrillation. Int
J Cardiol 2000;75:227–32.
860 Lim et al. JACC Vol. 61, No. 8, 2013
LA Thrombogenesis in AF February 26, 2013:852–6011. Goette A, Ittenson A, Hoffmanns P, et al. Increased expression of
P-selectin in patients with chronic atrial fibrillation. Pacing Clin
Electrophysiol 2000;23:1872–5.
12. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of
thrombogenesis in chronic atrial fibrillation: effects of warfarin treat-
ment. Br Heart J 1995;73:527–33.
13. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging
thrombosis and inflammation. Circulation 2002;105:2130–2.
14. Pongratz G, Brandt-Pohlmann M, Henneke KH, et al. Platelet
activation in embolic and preembolic status of patients with nonrheu-
matic atrial fibrillation. Chest 1997;111:929–33.
15. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is
associated with local cardiac platelet activation and endothelial dys-
function. J Am Coll Cardiol 2008;51:1790–3.
16. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation
activates platelets and coagulation in a time-dependent manner: a
study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol
1997;29:106–12.
17. Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P
and CD63, mean platelet volume, and soluble/platelet P-selectin as
indexes of platelet function in atrial fibrillation: a comparison of
“healthy control subjects” and “disease control subjects” in sinus
rhythm. J Am Coll Cardiol 2007;49:1957–64.
18. Ferroni P, Pulcinelli FM, Lenti L, Gazzaniga PP. Is soluble P-selectin
determination a more reliable marker of in vivo platelet activation than
CD62P flow cytometric analysis? Thromb Haemost 1999;81:472–3.
19. Atalar E, Haznedaroglu IC, Acil T, et al. Patients with paroxysmal
atrial fibrillation but not paroxysmal supraventricular tachycardia
display evidence of platelet activation during arrhythmia. Platelets
2003;14:407–11.
20. Yamashita T, Sekiguchi A, Iwasaki YK, et al. Thrombomodulin and
tissue factor pathway inhibitor in endocardium of rapidly paced rat
atria. Circulation 2003;108:2450–2.
21. Nakamura Y, Nakamura K, Fukushima-Kusano K, et al. Tissue factor
expression in atrial endothelia associated with nonvalvular atrial
fibrillation: possible involvement in intracardiac thrombogenesis.
Thromb Res 2003;111:137–42.
22. Black IW, Chesterman CN, Hopkins AP, Lee LC, Chong BH,
Walsh WF. Hematologic correlates of left atrial spontaneous echo
contrast and thromboembolism in nonvalvular atrial fibrillation. J Am
Coll Cardiol 1993;21:451–7.
23. Schotten U, Ausma J, Stellbrink C, et al. Cellular mechanisms of
depressed atrial contractility in patients with chronic atrial fibrillation.
Circulation 2001;103:691–8.
24. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri
A. Histological substrate of atrial biopsies in patients with lone atrial
fibrillation. Circulation 1997;96:1180–4.
25. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand
factor in the endocardium as a local predisposing factor for thrombo-
genesis in overloaded human atrial appendage. J Am Coll Cardiol
2001;37:1436–42.
26. Stuhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction
induced by hyperhomocyst(e)inemia: role of asymmetric dimethylargi-
nine. Circulation 2003;108:933–8.
27. Stamler J, Mendelsohn ME, Amarante P, et al. N-acetylcysteine
potentiates platelet inhibition by endothelium-derived relaxing factor.
Circ Res 1989;65:789–95.28. Goette A, Hammwohner M, Bukowska A, et al. The impact of rapid
atrial pacing on ADMA and endothelial NOS. Int J Cardiol 2012;
154:141–6.
29. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethy-
larginine independently predicts total and cardiovascular mortality in
individuals with angiographic coronary artery disease (the Ludwig-
shafen Risk and Cardiovascular Health study). Clin Chem 2007;53:
273–83.
30. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in
initiation and perpetuation of atrial fibrillation: a systematic review of
the published data. J Am Coll Cardiol 2007;50:2021–8.
31. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein
elevation in patients with atrial arrhythmias: inflammatory mecha-
nisms and persistence of atrial fibrillation. Circulation 2001;104:
2886 –91.
32. Rotter M, Jais P, Vergnes MC, et al. Decline in C-reactive protein
after successful ablation of long-lasting persistent atrial fibrillation.
J Am Coll Cardiol 2006;47:1231–3.
33. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in
acute coronary syndromes. N Engl J Med 2003;348:1104–11.
34. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD.
Membrane-associated CD40L and sCD40L in atherothrombotic
disease. Thromb Haemost 2003;90:377–84.
35. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated
platelets triggers an inflammatory reaction of endothelial cells. Nature
1998;391:591–4.
36. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between
sinus rhythm, treatment, and survival in the Atrial Fibrillation
Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Circulation 2004;109:1509–13.
37. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between
daily atrial tachyarrhythmia burden from implantable device diagnos-
tics and stroke risk: the TRENDS study. Circ Arrhythm Electro-
physiol 2009;2:474–80.
38. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation
and the risk of stroke. N Engl J Med 2012;366:120–9.
39. Grimm RA, Stewart WJ, Arheart K, Thomas JD, Klein AL. Left
atrial appendage “stunning” after electrical cardioversion of atrial
flutter: an attenuated response compared with atrial fibrillation as the
mechanism for lower susceptibility to thromboembolic events. J Am
Coll Cardiol 1997;29:582–9.
40. Ghali WA, Wasil BI, Brant R, Exner DV, Cornuz J. Atrial flutter and
the risk of thromboembolism: a systematic review and meta-analysis.
Am J Med 2005;118:101–7.
41. Rosenberg RD. Biochemistry of heparin antithrombin interactions,
and the physiologic role of this natural anticoagulant mechanism. Am J
Med 1989;87:2S–9S.
42. Bauer KA. Laboratory markers of coagulation activation. Arch Pathol
Lab Med 1993;117:71–7.
43. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of
systemic nitric oxide synthase inhibition with asymmetrical dimethy-
larginine in humans. Circulation 2004;109:172–7.
44. Marcovecchio ML, Widmer B, Dunger DB, Dalton RN. Effect of
acute variations of insulin and glucose on plasma concentrations of
asymmetric dimethylarginine in young people with type 1 diabetes.
Clin Sci (Lond) 2008;115:361–9.Key Words: atrial fibrillation y atrium y stroke y thrombosis.
